title: Gastric administration of recombinant 65 kDa heat shock protein delays the severity of type II collagen induced arthritis in mice.
abstract: OBJECTIVE
  The 65 kDa heat shock protein (HSP) chaperonin is a highly conserved intracellular protein. HSP are involved in the pathogenesis of arthritis, but are not able to induce experimental arthritis. T cell clones recognizing the 180-188 amino acid sequence of 65 kDa HSP are present in inflamed synovium of both adjuvant arthritis and rheumatoid arthritis (RA). Oral administration of bovine collagen II or co-chaperonin 10 kDa HSP has been shown to induce an immune tolerance state to collagen induced arthritis (CIA). We investigate the effect of oral gavage with 65 kDa HSP on CIA.
  
  
  METHODS
  We immunized 6-8-week-old DBA1 male mice with bovine type II collagen. A group of 25 mice were given oral recombinant mycobacterial 65 kDa HSP before immunization (30 microg in 200 microl phosphate buffered saline (PBS) at Days -7, -5, -2) while PBS alone was administered in 27 controls. A 3rd group was fed 65 kDa HSP according to the same protocol but was not immunized with collagen II (n = 8). The clinical arthritis score was recorded 3 times/week until Day 60. Antibodies to collagen II were determined by ELISA.
  
  
  RESULTS
  The incidence of arthritis was comparable in the 2 groups (72 vs 70%). The onset of arthritis was not delayed in mice fed HSP. However, the severity of arthritis was lower 10 days after arthritis onset in animals fed 65 kDa HSP (clinical score 1.83 +/- 0.79 vs 2.74 +/- 1.1; p < 0.0001). No animals in Group 3 had arthritis. Serum IgG anti-type II collagen levels were decreased in HSP treated mice (optical density 0.33 +/- 0.21 vs 0.46 +/- 0.21; p < 0.0001). However, the ratio of IgG1/IgG2a antitype II collagen antibody response remained unchanged in the mice fed 65 kDa HSP.
  
  
  CONCLUSIONS
  These results suggest that oral administration of 65 kDa HSP may diminish collagen induced arthritis.
authors.affiliation: Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Unité INSERM U475, Montpellier, France.
authors.forename: C
authors.initials: C
authors.lastname: Jorgensen
authors.forename: E
authors.initials: E
authors.lastname: Gedon
authors.forename: C
authors.initials: C
authors.lastname: Jaquet
authors.forename: J
authors.initials: J
authors.lastname: Sany
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage*; D001168:Arthritis / Q000139:chemically induced / Q000175:diagnosis / Q000517:prevention & control*; D001426:Bacterial Proteins; D018834:Chaperonin 60; D018833:Chaperonins / Q000008:administration & dosage*; D003094:Collagen / Q000276:immunology / Q000494:pharmacology; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D018834:Chaperonin 60; D007074:Immunoglobulin G; D011994:Recombinant Proteins; C074119:heat-shock protein 65, Mycobacterium; D003094:Collagen; D018833:Chaperonins